Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study.
- Author:
Young Sup WOO
1
;
Joo Eon PARK
;
Do Hoon KIM
;
Inki SOHN
;
Tae Yeon HWANG
;
Young Min PARK
;
Duk In JON
;
Jong Hyun JEONG
;
Won Myong BAHK
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Blonanserin; Schizophrenia; Augmentation; Treatment response; Antipsychotics
- MeSH: Antipsychotic Agents*; Humans; Prospective Studies*; Schizophrenia
- From:Psychiatry Investigation 2016;13(4):458-467
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: The purpose of this study was to investigate the efficacy and tolerability of atypical antipsychotics (AAPs) with augmentation by blonanserin in schizophrenic patients. METHODS: aA total of 100 patients with schizophrenia who were partially or completely unresponsive to treatment with an AAP were recruited in this 12-week, open-label, non-comparative, multicenter study. Blonanserin was added to their existing AAP regimen, which was maintained during the study period. Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at weeks 2, 4, 8, and 12. Predictors for PANSS response (≥20% reduction) were investigated. RESULTS: The PANSS total score was significantly decreased at 12 weeks of blonanserin augmentation (-21.0±18.1, F=105.849, p<0.001). Moreover, 51.0% of participants experienced a response at week 12. Premature discontinuation of blonanserin occurred in 17 patients (17.0%); 4 of these patients dropped out due to adverse events. The patients who benefited the most from blonanserin were those with severe symptoms despite a treatment with a higher dose of AAP. CONCLUSION: Blonanserin augmentation could be an effective strategy for patients with schizophrenia who were partially or completely unresponsive to treatment with an AAP.
